Jeito logo.png
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
01. November 2022 06:02 ET | Jeito Capital
                                                            Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with...